ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
ARS PHARMACEUTICALS INC
NASDAQ:SPRY (5/1/2024, 7:23:27 PM)
After market: 9.33 0 (0%)9.33
+0.63 (+7.24%)
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 24 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The firm has designed and developed neffy to provide injection-like absorption of epinephrine, at a low dose, easy-to-use small nasal spray device.
Company Info
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 120
San Diego CALIFORNIA
P: 18587719307
Employees: 24
Website: https://ars-pharma.com/
SPRY News
2 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
2 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandCHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024
a month ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)a month ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC)...
a month ago - InvestorPlaceSPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
a month ago - BusinessInsiderSPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips ARS Pharmaceuticals (NASDAQ:SPRY) just reported results for the fourth quarter ...
SPRY Twits
Here you can normally see the latest stock twits on SPRY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
